Search Results
Your search for all items matches 33070 pages
Showing 1 - 50Adding Perioperative Nivolumab to Neoadjuvant Chemotherapy in Resectable NSCLC: CheckMate 77T
As reported in The New England Journal of Medicine by Tina Cascone, MD, PhD, and colleagues, interim analysis in the phase III CheckMate 77T trial has shown that the addition of perioperative nivolumab to neoadjuvant chemotherapy improved event-free survival in patients with resectable non–small...
Nivolumab/Ipilimumab Boost in Metastatic Urothelial Carcinoma
In a German-Austrian phase II study (TITAN-TCC) reported in JAMA Oncology, Grimm et al described outcomes with the use of nivolumab plus ipilimumab as an immunotherapeutic boost in metastatic urothelial carcinoma. Study Details In the multicenter trial, 169 patients were enrolled into two cohorts...
Pertuzumab Plus Trastuzumab for Advanced Biliary Tract Cancer With HER2/3 Alterations
As reported in the Journal of Clinical Oncology by Cannon et al, findings in a cohort of the phase II Targeted Agent and Profiling Utilization Registry (TAPUR) basket study showed that the combination of pertuzumab and trastuzumab was active in patients with advanced biliary tract cancer with...
NCCN Clinical Practice Guidelines in Oncology: 2024 Updates
The National Comprehensive Cancer Network® published its first set of Clinical Practice Guidelines in Oncology (NCCN Guidelines®) in 1996, covering eight tumor types. Currently, guidelines are available for more than 60 tumor types, subtypes, and related topics. The NCCN’s 29th Annual Conference...
End-of-Life Systemic Therapy May Not Improve Survival in Patients With Advanced Solid Tumors
Systemic therapy may offer no significant improvement in overall survival in patients with advanced solid tumors, according to a recent study published by Canavan et al in JAMA Oncology. Study Methods and Results In the recent study, the investigators analyzed the de-identified data of over 78,000...
Bariatric Surgery May Help Reduce the Risk of Breast Cancer in Female Patients With Obesity, Hyperinsulinemia
Bariatric surgery may be associated with a reduced risk of breast cancer in female patients with obesity, especially those with hyperinsulinemia at the time of surgery, according to a recent study published by Kristensson et al in JAMA Surgery. Bariatric surgery is known to be one of the most...
Multiple Myeloma: Is MRD Status at 1 Year After Treatment Predictive of Survival?
Results from the Prognostic Immunophenotyping in Myeloma Response (PRIMeR) study, reported in the Journal of Clinical Oncology by Marcelo C. Pasquini, MD, MS, and colleagues, found that undetectable measurable residual disease (MRD) status at 1 year after autologous hematopoietic cell...
Definitive Concurrent Chemoradiotherapy for Unresectable Locally Advanced Esophageal Cancer: Comparison of Agents
In a Chinese phase III trial (CRTCOESC) reported in the Journal of Clinical Oncology, Jia et al found that neither capecitabine nor XELOX (capecitabine, oxaliplatin) improved 2-year overall survival vs cisplatin/fluorouracil as part of definitive concurrent chemoradiotherapy in patients with...
FDA Grants Accelerated Approval to Tarlatamab-dlle for Extensive-Stage SCLC
On May 16, the U.S. Food and Drug Administration (FDA) granted accelerated approval to tarlatamab-dlle (Imdelltra), a bispecific T-cell engager immunotherapy targeting delta-like ligand 3 and CD3, for patients with extensive-stage small cell lung cancer (SCLC) with disease progression on or after...
Half-Matched Family Donors May Improve ASCT Outcomes in Hispanic Patients With ALL
Researchers have found that allogeneic stem cell transplantation from a haploidentical relative may significantly increase the rate of success in Hispanic patients with acute lymphoblastic leukemia (ALL), according to a recent study published by Ashouri et al in Leukemia Research. Background In...
Childhood Adiposity and Risk for Breast Cancer
Investigators have uncovered that a higher adiposity in childhood may lead to less dense tissue formation and decrease the risk of breast cancer, according to a recent study published by Vabistsevits et al in Nature Communications. Background As a result of the rising incidence of breast cancer,...
Donepezil for the Treatment of Cognitive Impairment in Breast Cancer Survivors After Adjuvant Chemotherapy
In the phase III WF-97116 trial reported in the Journal of Clinical Oncology, Rapp et al found that treatment with the cognitive enhancer donepezil did not improve memory or other cognitive functions vs placebo in breast cancer survivors with cancer-related cognitive impairment 1 to 5 years after...
Providing Culturally Sensitive Palliative Care to Children With Cancer
In the fall of 2023, Justin Baker, MD, took on the role of Chief of the Division of Quality of Life and Pediatric Palliative Care and Director of the Quality of Life for All Program, Stanford Medicine Children’s Health, Stanford, California. He formerly worked at St. Jude Children’s Research...
Daniel M. Geynisman, MD, Named New JNCCN Editor-in-Chief
Daniel M. Geynisman, MD, has been announced as the new Editor-in-Chief for JNCCN—Journal of the National Comprehensive Cancer Network. Dr. Geynisman is Associate Professor in the Department of Hematology/Medical Oncology and Chief of the Division of Genitourinary Medical Oncology at Fox Chase...
FDA Grants Accelerated Approval to Lisocabtagene Maraleucel for Relapsed or Refractory Follicular Lymphoma
On May 15, the U.S. Food and Drug Administration (FDA) granted accelerated approval to the chimeric antigen receptor (CAR) T-cell therapy lisocabtagene maraleucel (Breyanzi) for adult patients with relapsed or refractory follicular lymphoma who have received two or more prior lines of systemic...
Newly Identified Genetic Variants Linked to Breast Cancer Risk in Women of African Ancestry
Researchers have uncovered novel genetic variants potentially associated with a higher risk of breast cancer–related mortality among women of African ancestry, according to a recent study published by Jia et al in Nature Genetics. Background Breast cancer is the most common type of cancer among...
Plant-Based Diet May Offer Benefit in Patients With Prostate Cancer
A plant-based diet may help reduce the risk of disease progression in patients with prostate cancer, according to a recent study published by Liu et al in JAMA Network Open. Background Prostate cancer is the most common type of cancer among men. Plant-based diets—which are becoming increasingly...
Third-Line Therapy for Transplant-Ineligible DLBCL
This is Part 3 of Treatment Strategies for Transplant-Ineligible Relapsed/Refractory DLBCL, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Jason Westin, Dai Chihara, and Caron A. Jacobson discuss the third-line treatment of...
Late Relapsing DLBCL
This is Part 2 of Treatment Strategies for Transplant-Ineligible Relapsed/Refractory DLBCL, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Jason Westin, Dai Chihara, and Caron A. Jacobson discuss the treatment of late...
Early Relapsed/Refractory DLBCL
This is Part 1 of Treatment Strategies for Transplant-Ineligible Relapsed/Refractory DLBCL, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Jason Westin, Dai Chihara, and Caron A. Jacobson discuss the treatment of early...
AACR Cancer Disparities Progress Report 2024 Highlights Ongoing Health Inequities Experienced by Racial and Ethnic Minorities
Despite the extraordinary progress against cancer in the United States—illustrated by the continuing decline in the overall mortality rate, which fell by 33% between 1991 and 2020, and the increasing numbers of cancer survivors (over 18 million and climbing)—the burden of cancer remains...
Previously Untreated Mantle Cell Lymphoma: Ibrutinib, Immunochemotherapy, and ASCT
As reported in The Lancet by Martin Dreyling, MD, PhD, and colleagues, results in the European Mantle Cell Lymphoma Network phase III TRIANGLE trial indicate that the addition of ibrutinib to immunochemotherapy and autologous stem cell transplantation (ASCT) significantly improved failure-free...
Marker for Distinguishing Renal Cell Carcinoma From Benign Renal Masses
In a study reported in the Journal of Clinical Oncology, Xu et al found that higher levels of preoperative plasma kidney injury molecule-1 (pKIM-1) distinguished renal cell carcinoma from benign renal masses. As stated by the investigators, “Both clear cell and papillary renal cell carcinoma...
FDA Approves HPV Self-Collection Solution
On May 15, Roche announced the U.S. Food and Drug Administration (FDA) approval of its human papillomavirus (HPV) self-collection solution—one of the first of such tests available in the United States. Screening for HPV can help identify women who are at risk of developing cervical cancer so that...
Disparities in Melanoma Outcomes Among Black Patients
Investigators may have uncovered sex-based disparities in the detection and survival of melanoma in Black patients, according to a recent study published by Steadman et al in the Journal of Surgical Oncology. Background Melanoma is an aggressive type of skin cancer that accounts for about 75% of...
Chemotherapy May Accelerate Physical Decline in Older Patients With Early-Stage Breast Cancer
Investigators have found that female patients aged 65 years or older with high-risk breast cancer who are treated with chemotherapy may be more likely to experience a substantial decline in physical function, according to a recent study published by Sedrak et al in the Journal of Cancer...
Study Reveals Potential Overtreatment of DCIS in Older Women With Limited Life Expectancy
Ductal carcinoma in situ (DCIS) may often be overtreated in older women with limited life expectancy, according to research presented during the 2024 Society of Surgical Oncology (SSO) Annual Meeting.1 The retrospective analysis of the Surveillance, Epidemiology, and End Results (SEER)-Medicare...
T-DXd for Advanced Solid Tumors With Activating HER2 Mutations
As reported in The Lancet Oncology by Bob T. Li, MD, PhD, MPH, and colleagues, the phase II DESTINY-PanTumor01 trial showed activity of fam-trastuzumab deruxtecan-nxki (T-DXd) in patients with unresectable or metastatic solid tumors that have specific activating HER2 mutations. The antibody-drug...
Childhood Cancer Survivors: Genetic Risk Factors for Treatment-Related Type 2 Diabetes Mellitus
In a study reported in the Journal of Clinical Oncology, Im et al found that genetic variants associated with a risk of treatment-related type 2 diabetes mellitus among childhood cancer survivors of African or European ancestry posed a higher risk of diabetes among those of African ancestry. As...
Children’s Cancer Cause Opens Applications for the 2024 Survivorship Champion’s Prize
The Children’s Cancer Cause announced that the organization is accepting applications for its 2024 Survivorship Champion’s Prize. Overview of the Prize The Survivorship Champion’s Prize, totaling $10,000, is presented by Children’s Cancer Cause annually to a group, program, or institution...
Appendectomy May Lower Risk of Colorectal Cancer Subtype
Appendectomy may be associated with a reduced risk of a colorectal cancer subtype positive for the tumor-promoting Fusobacterium nucleatum bacteria, according to a recent study published by Kawamura et al in the Annals of Surgery. Background Despite being historically dismissed as an unnecessary...
Lymphoid Neoplasms: European National Health Expenditure and Long-Term Survival
In an analysis of the EUROCARE-6 data set reported in The Lancet Oncology, Milena Sant, MD, and colleagues found that patients with lymphoid neoplasms from European countries with greater health expenditure had improved 10-year age-standardized relative survival. Study Details The study involved...
Doublet for Previously Treated Patients With Advanced Leiomyosarcoma
In a phase Ib study reported in the Journal of Clinical Oncology, Van Tine et al established the recommended phase II dose of oral unesbulin in combination with dacarbazine for patients with locally recurrent, unresectable or metastatic, relapsed or refractory leiomyosarcoma. Unesbulin is a small...
Survey Finds Majority of Patients With Cancer and Survivors Have or Expect to Incur Medical Debt—Even Those With Insurance
Nearly half (49%) of patients with cancer and cancer survivors report being burdened by medical debt, alongside some (13%) who report expecting to incur medical debt as part of their treatment plan, according to a new Survivor Views survey conducted by the American Cancer Society Cancer Action...
Colorectal Cancer Incidence Is Rising Among Teenagers and Young Adults
The incidence of colorectal cancer has risen significantly among younger U.S. patients over the past 2 decades, according to new findings presented by Mohamed et al at Digestive Disease Week (DDW) 2024 (Abstract Mo1149) and simultaneously published in Gastroenterology. Background “Colorectal cancer ...
Oral Rinse Could Provide Early Screening for Gastric Cancer
A simple oral rinse may lead to early detection of gastric cancer, according to new findings presented by Perati et al at Digestive Disease Week (DDW) 2024 (Abstract 949) and simultaneously published in Gastroenterology. Background Gastric cancer is the fourth leading cause of cancer mortality...
Venetoclax Plus Hypomethylating Agents: Analyzing Standard-of-Care Outcomes in Older Patients With AML
Standard-of-care treatment comprising venetoclax plus hypomethylating agents was found to be safe and effective in some patients aged 80 years and older with acute myeloid leukemia (AML), according to a recent study published by Madarang et al in Blood Neoplasia. Background Older adult patients...
A Delay in Diagnosis Led to Advanced Prostate Cancer
Cancer is not an unfamiliar disease to me. My mother died of cancer when I was 12. My oldest sister died of breast cancer, an aunt died of cancer (I don’t know which type), and my older brother is a prostate cancer survivor. So, when I was diagnosed with prostate cancer in October 2021, the news...
NIH’s New Cancer Screening Research Network and Cancer Screening Technologies
The National Institutes of Health (NIH) has launched the Cancer Screening Research Network, a clinical trials network to evaluate emerging cancer screening technologies. The new network will support the Biden-Harris Administration’s Cancer Moonshot initiative by investigating how to identify cancer ...
Pirtobrutinib in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
On December 1, 2023, pirtobrutinib (Jaypirca), a selective, noncovalent Bruton’s tyrosine kinase (BTK) inhibitor that inhibits both wild-type and C481-mutant BTK with equal low nanomolar potency and is designed to address several of the limitations of covalent BTK inhibitors, was granted...
Pembrolizumab/Chemotherapy for Advanced Biliary Tract Cancer
On October 31, 2023, pembrolizumab (Keytruda) was approved for use with gemcitabine/cisplatin in first-line treatment of patients with locally advanced unresectable or metastatic biliary tract cancer.1 Supporting Efficacy Data Approval was based on the double-blind KEYNOTE-966 trial...
Belzutifan in Previously Treated Advanced Renal Cell Carcinoma
On December 14, 2023, the hypoxia-inducible factor inhibitor belzutifan (Welireg) was approved for patients with unresectable locally advanced or metastatic clear cell renal cell carcinoma with disease progression on previous treatment with a PD-1 or PD-L1 inhibitor and a vascular endothelial...
Enfortumab Vedotin-ejfv Plus Pembrolizumab Improves Survival vs Platinum-Based Chemotherapy in Advanced Urothelial Cancer
As reported in The New England Journal of Medicine by Thomas Powles, MD, Barts Cancer Institute Biomedical Research Centre, Queen Mary University of London, and colleagues, the phase III EV-302 trial has shown that the combination of the antibody–drug conjugate enfortumab vedotin-ejfv, which is...
Cell-Free DNA Blood-Based Test and Next-Generation Multitarget Stool DNA Test in Colorectal Cancer Screening
In two studies reported in The New England Journal of Medicine, investigators found that a cell-free DNA (cfDNA) blood-based test (ECLIPSE study)1 and a next-generation multitarget stool DNA test (BLUE-C study)2 both showed high sensitivity for colorectal cancer and high specificity for advanced...
Whole-Pelvic Radiation Therapy for Unfavorable-Risk Prostate Cancer
As reported in the Journal of Clinical Oncology by Sayan et al, analysis of long-term findings from the phase III Dana-Farber Cancer Institute Trial 05-043 showed that whole-pelvic radiation therapy (WPRT) was associated with favorable survival outcomes vs prostate-only radiation therapy (PORT)...
Head and Neck Cancer: Osteoradionecrosis of the Jaw Classification System
In a single-institution study reported in the Journal of Clinical Oncology, Watson et al identified risk factors for osteoradionecrosis of the jaw and developed a classification system for the condition in patients receiving radiation therapy for head and neck cancer. Study Details The study...
Impact of Age on Outcomes in Endometrial Cancer
In an analysis of data from the PORTEC-1, -2, and -3 trials reported in The Lancet Oncology, Wakkerman et al found that older age was associated with more aggressive tumor features and poorer outcomes in patients with endometrial cancer. Study Details The analysis included data from 1,801...
Novel PET Agent May Accelerate Imaging in Patients With Clear Cell Renal Cell Carcinoma
The novel investigational positron-emission tomography (PET) imaging agent gallium (Ga)-68–DPI-4452 may offer rapid and accurate visualization of lesions in patients with clear cell renal cell carcinoma, according to a recent study published by Hofman et al in The Journal of Nuclear Medicine. The...
Chemical-Related Epigenetic Modifications May Increase Risk of Prostate Cancer Among Firefighters
Exposure to certain chemicals while on the job may increase the risk of prostate cancer among firefighters, according to a recent study published by Quaid et al in Environmental and Molecular Mutagenesis. Background Prostate cancer has the highest incidence of any cancer type among U.S. male...
New Policy Statement Addresses Social, Economic, and Environmental Factors Influencing Cancer Care, Outcomes
ASCO’s new policy statement highlights the need for formalized efforts to address health-related social needs and outlines ways to address social determinants of health (SDOH) in cancer care. Social determinants are defined as conditions in which people are born, grow, live, work, and age, which...
